Zimmer BiometZBHEarnings & Financial Report
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Revenue
$2.1B
Gross Profit
$1.5B
Operating Profit
$300.0M
Net Profit
$152.8M
Gross Margin
71.5%
Operating Margin
14.4%
Net Margin
7.4%
YoY Growth
7.0%
EPS
$0.77
Zimmer Biomet Q2 FY2025 Financial Summary
Zimmer Biomet reported revenue of $2.1B (up 7.0% YoY) for Q2 FY2025, with a net profit of $152.8M (down 37.1% YoY) (7.4% margin). Cost of goods sold was $592.2M, operating expenses totaled $1.2B.
Key Financial Metrics
| Total Revenue | $2.1B |
|---|---|
| Net Profit | $152.8M |
| Gross Margin | 71.5% |
| Operating Margin | 14.4% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Zimmer Biomet Q2 FY2025 revenue of $2.1B breaks down across 4 segments, led by Knees at $826.0M (39.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Knees | $826.0M | 39.8% |
| SET | $550.6M | 26.5% |
| Hips | $536.1M | 25.8% |
| Technology And Data Bone Cement And Surgical | $164.6M | 7.9% |
Zimmer Biomet Revenue by Segment — Quarterly Trend
Zimmer Biomet revenue by segment across the last 4 reported quarters, showing how each business line (such as Knees and SET) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Knees | — | $911.0M | $792.4M | $826.0M |
| SET | — | $587.6M | $541.5M | $550.6M |
| Hips | — | $555.4M | $506.2M | $536.1M |
| Technology And Data Bone Cement And Surgical | — | $189.8M | $161.3M | $164.6M |
Zimmer Biomet Annual Revenue by Year
Zimmer Biomet annual revenue history includes year-by-year totals (for example, 2025 revenue was $8.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $8.2B |
| 2024 | $7.7B |
| 2023 | $7.4B |
| 2022 | $6.9B |
Zimmer Biomet Quarterly Revenue & Net Profit History
Zimmer Biomet results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.1B | +9.3% | $238.3M | 11.4% |
| Q4 FY2025 | $2.2B | +10.9% | $139.4M | 6.2% |
| Q3 FY2025 | $2.0B | +9.7% | $230.9M | 11.5% |
| Q2 FY2025 | $2.1B | +7.0% | $152.8M | 7.4% |
| Q1 FY2025 | $1.9B | +1.1% | $182.0M | 9.5% |
| Q4 FY2024 | $2.0B | +4.3% | $239.5M | 11.8% |
| Q3 FY2024 | $1.8B | +4.0% | $249.1M | 13.7% |
| Q2 FY2024 | $1.9B | +3.9% | $242.8M | 12.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.94B | $1.82B | $2.02B | $1.91B | $2.08B | $2.00B | $2.24B | $2.09B |
| YoY Growth | 3.9% | 4.0% | 4.3% | 1.1% | 7.0% | 9.7% | 10.9% | 9.3% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $21.52B | $21.72B | $21.37B | $22.18B | $22.87B | $23.49B | $23.09B | $22.72B |
| Liabilities | $8.77B | $9.34B | $8.89B | $9.78B | $10.33B | $10.72B | $10.39B | $10.04B |
| Equity | $12.74B | $12.37B | $12.47B | $12.40B | $12.53B | $12.76B | $12.70B | $12.68B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $369.4M | $395.7M | $506.3M | $382.8M | $378.2M | $418.7M | $517.4M | $359.4M |